We’ve extended the submission deadline! The new deadline for research submissions is November 16th.
The editors of PLOS Medicine together with guest editors Claudia Denkinger, Richard Chaisson, and Mark Hatherill announce a forthcoming Special Issue focused on new approaches to alleviate the individual and epidemiological burden of tuberculosis. Research submissions are now being invited, with a deadline of November 16, 2018. Submit now.
On September 26th, the United Nations will hold a High-Level Meeting on tuberculosis (TB), the theme of which is “United to end tuberculosis: an urgent global response to a global epidemic”. This Meeting is expected to result in an ambitious Political Declaration on TB and commitment from heads of state to invest in ending TB.
The leading infectious cause of death worldwide, tuberculosis demands an urgent response that will realistically enable the disease’s elimination. Despite increases in funding for TB prevention and care in recent years, progress towards the UN Sustainable Development Goals for TB elimination still lags behind targets, underscoring the need for novel approaches.
The PLOS Medicine editors are therefore excited to announce this special issue, to be published in spring of 2019, guest edited by Dr Claudia Denkinger, Head of TB at FIND, Dr Richard Chaisson, director of the Johns Hopkins University Center for Tuberculosis Research, and Dr Mark Hatherill, Director of the South African Tuberculosis Vaccine Initiative. Alongside research articles, the special issue will include commissioned Perspectives by leaders in the field.
For the special issue, we invite high-quality research studies with the potential to inform clinical practice or open new avenues of clinical research, with a focus on:
- Discovery and validation of novel biomarkers (including prognostic markers and predictors of response to treatment) as well as diagnostic technologies to improve case detection (thereby reaching the “missing millions”) and to rapidly inform therapy of drug-resistant infections.
- Development of new treatments for tuberculosis disease and infection, including clinical trials, clinically applicable pharmacokinetic and drug-drug interaction studies, and clinically relevant translational research evaluating novel drugs and drug combinations.
- Testing of vaccines developed for the prevention of tuberculosis infection, prevention of tuberculosis disease, or as therapeutic vaccines for prevention of recurrence after treatment.
- Implementation studies testing new strategies to find and treat tuberculosis disease and infection and to enhance adherence to therapy.
Please submit your manuscript at: http://journals.plos.org/plosmedicine/s/submit-now. The deadline is November 16th, 2018.
Questions about the special issue can be directed to email@example.com.
Featured Image Credit: GDJ, Pixabay and NIAID, Flickr